<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ophthalmology</journal-id><journal-title-group><journal-title xml:lang="ru">Офтальмология</journal-title><trans-title-group xml:lang="en"><trans-title>Ophthalmology in Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1816-5095</issn><issn pub-type="epub">2500-0845</issn><publisher><publisher-name>Ophthalmology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18008/1816-5095-2021-3S-727-734</article-id><article-id custom-type="elpub" pub-id-type="custom">ophthalmology-1650</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Статьи</subject></subj-group></article-categories><title-group><article-title>Томографические параметры рецидивирующего течения макулярного отека при окклюзии вен сетчатки на фоне антиангиогенной терапии</article-title><trans-title-group xml:lang="en"><trans-title>Tomographic Parameters of Recurrent Macular Edema Due to Retinal Vein Occlusion during Antiangiogenic Therapy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хохлова</surname><given-names>Д. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Khokhlova</surname><given-names>D. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хохлова Дарья Юрьевна, кандидат медицинских наук, врач-офтальмолог </p><p>ул. Дзержинского, 17а, Челябинск, 454129</p></bio><bio xml:lang="en"><p>Khokhlova Daria Yu., PhD, ophthalmologist</p><p>Dzerzhinsky str., 17A, Chelyabinsk, 454129</p></bio><email xlink:type="simple">dar.yu@mail.yu</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лоскутов</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Loskutov</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Лоскутов Игорь Анатольевич, доктор медицинских наук, старший научный сотрудник отдела </p><p>ул. Россолимо, 11а, б, Москва, 119021</p></bio><bio xml:lang="en"><p>Loskutov Igor A., MD, senior research officer</p><p>Rossolimo str., 11A, B, Moscow, 119021</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>МАУЗ «Городская клиническая больница № 11»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Clinical Hospital № 11</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт глазных болезней»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Research Institute of Eye Diseases</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>22</day><month>10</month><year>2021</year></pub-date><volume>18</volume><issue>3S</issue><fpage>727</fpage><lpage>734</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Хохлова Д.Ю., Лоскутов И.А., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Хохлова Д.Ю., Лоскутов И.А.</copyright-holder><copyright-holder xml:lang="en">Khokhlova D.Y., Loskutov I.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ophthalmojournal.com/opht/article/view/1650">https://www.ophthalmojournal.com/opht/article/view/1650</self-uri><abstract><sec><title>Цель</title><p>Цель: определить томографические параметры макулярной зоны, влияющие на рецидивирующее течение макулярного отека при окклюзии вен сетчатки.</p></sec><sec><title>Пациенты и методы</title><p>Пациенты и методы: в ретроспективное исследование были включены 54 пациента (54 глаза) с макулярным отеком давностью не более 3 месяцев, у которых после трех инъекций афлиберцепта наблюдалась полная резорбция отека с его последующим рецидивом, что требовало продолжения терапии. Проведено стандартное офтальмологическое обследование, спектральная оптическая когерентная томография, интравитреальное введение афлиберцепта по стандартной методике, статистический анализ данных.</p></sec><sec><title>Результаты</title><p>Результаты: рецидив макулярного отека развивался в среднем через 6,3 ± 1,2 недели после трех инъекций афлиберцепта. Нами выявлены наиболее значимые прогностические томографические параметры, влияющие на рецидивирующее течение макулярного отека на фоне интравитреального введения афлиберцепта: толщина сетчатки в фовеа более 500 мкм (ОR 2,1, р = 0,01), наличие отслойки нейроэпителия (ОR 5,1, р = 0,001), наличие гиперрефлективных включений (ОR 3,7, р = 0,03), альтерация наружной пограничной мембраны (ОR 4,7, р = 0,01), альтерация внутренних, наружных сегментов фоторецепторов и зоны их сочленения (ОR 3,4, р = 0,01), альтерация комплекса «пигментный эпителий / мембрана Бруха» (ОR 2,1, р = 0,02).</p></sec><sec><title>Заключение</title><p>Заключение. На рецидивирующее течение макулярного отека при окклюзии вен сетчатки на фоне антиангиогенной терапии влияют исходные томографические параметры. Полученные нами результаты могут иметь значение в прогнозировании длительности и результативности лечения у конкретного пациента в начале заболевания, что делает подход к ведению более персонализированным, перспективным в экономическом, социальном и психологическом аспекте.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose</title><p>Purpose: to establish the tomographic parameters to predict the recurrent of macular edema due to retinal vein occlusion.</p></sec><sec><title>Patients and methods</title><p>Patients and methods. This is a retrospective study of 54 patients (54 eyes) with macular edema, no more than 3 months old, who had recurrent of macular edema after 3 intravitreal injections of aflibercept. Standard ophthalmological examination, spectral optical coherence tomography, intravitreal injections of aflibercept according to instruction, and statistical analysis of the data were conducted.</p></sec><sec><title>Results</title><p>Results. Recurrence of macular edema developed on average 6.3 ± 1.2 weeks after three injections of aflibercept. We identified of the most significant prognostic tomographic parameters affecting the recurrent of macular edema during intravitreal injections of aflibercept — central foveal thickness &gt; 500 μm (OR 2.1, p = 0.01), the presence of serous retinal detachment (OR 5.1, p = 0.001), the presence of hyperreflective foci (OR 3.7, p = 0.03), alteration of external limiting membrane (OR 4.7, p = 0.01), disruption of the photoreceptor innersegment/outer segment junction (OR 3.4, p = 0.01), disruption of retinal pigment epithelium (OR 2.1, p = 0.02).</p></sec><sec><title>Conclusion</title><p>Conclusion: the recurrent of macular edema with retinal vein occlusion during antiangiogenic therapy depends on baseline tomographic parameters. Our results can be important in predicting the duration and effectiveness of antiangiogenic therapy in a particular patient at the beginning of the disease, which makes the approach to management more personalized, promising in economic, social and psychological aspects.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>макулярный отек</kwd><kwd>афлиберцепт</kwd><kwd>окклюзия вен сетчатки</kwd><kwd>антиангиогенная терапия</kwd><kwd>спектральная оптическая когерентная томография</kwd></kwd-group><kwd-group xml:lang="en"><kwd>macular edema</kwd><kwd>aflibercept</kwd><kwd>retinal vein occlusion</kwd><kwd>antiangiogenic therapy</kwd><kwd>spectral optical coherence tomography</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Hayreh S.S. Retinal vein occlusion. Indian J. Ophthalmol. 1994;42(3):109–132.</mixed-citation><mixed-citation xml:lang="en">Hayreh S.S. Retinal vein occlusion. Indian J. Ophthalmol. 1994;42(3):109–132.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Scholl S., Augustin А., Loewenstein A. General pathophysiology of macular edema. Eur. J. Ophthalmol.2011;21;10–19. DOI: 10.5301/EJO.2010.6050</mixed-citation><mixed-citation xml:lang="en">Scholl S., Augustin А., Loewenstein A. General pathophysiology of macular edema. Eur. J. Ophthalmol.2011;21;10–19. DOI: 10.5301/EJO.2010.6050</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">McIntosh R.L., Rogers S.L., Lim L. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117:1113–1123. DOI: 10.1016/j.ophtha.2010.01.060</mixed-citation><mixed-citation xml:lang="en">McIntosh R.L., Rogers S.L., Lim L. Natural history of central retinal vein occlusion: an evidence-based systematic review. Ophthalmology. 2010;117:1113–1123. DOI: 10.1016/j.ophtha.2010.01.060</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Boyer D., Heier J., Brown D.M, Clark W.L., Vitti R. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024–1032. DOI: 10.1016/j.ophtha.2012.01.042. 1</mixed-citation><mixed-citation xml:lang="en">Boyer D., Heier J., Brown D.M, Clark W.L., Vitti R. Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS study. Ophthalmology. 2012;119(5):1024–1032. DOI: 10.1016/j.ophtha.2012.01.042. 1</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Brown D.M, Heier J.S, Lloyd Clark W., Boyer D.S., Vitti R., Berliner A.J. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-Year Results From the Phase 3 COPERNICUS Study. American Journal of Ophthalmology. 2013;155(3):429–437. DOI: 10.1016/j.ajo.2012.09.026</mixed-citation><mixed-citation xml:lang="en">Brown D.M, Heier J.S, Lloyd Clark W., Boyer D.S., Vitti R., Berliner A.J. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-Year Results From the Phase 3 COPERNICUS Study. American Journal of Ophthalmology. 2013;155(3):429–437. DOI: 10.1016/j.ajo.2012.09.026</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Holz F.G, Roider J., Ogura Y., Korobelnik J-F, Simader C., Groetzbach G., Vitti R., Berliner J., Hiemeyer F., Beckmann K., Zeitz O., Sandbrink R. VEGF trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. British Journal of Ophthalmology. 2013;97(3):278–284. DOI: 10.1136/bjophthalmol-2012-301504</mixed-citation><mixed-citation xml:lang="en">Holz F.G, Roider J., Ogura Y., Korobelnik J-F, Simader C., Groetzbach G., Vitti R., Berliner J., Hiemeyer F., Beckmann K., Zeitz O., Sandbrink R. VEGF trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. British Journal of Ophthalmology. 2013;97(3):278–284. DOI: 10.1136/bjophthalmol-2012-301504</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Korobelnik J., Holz F.G., Roider J., Ogura Y. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Ophthalmology. 2014;121(1):202–208. DOI: 10.1016/j.ophtha.2013.08.012</mixed-citation><mixed-citation xml:lang="en">Korobelnik J., Holz F.G., Roider J., Ogura Y. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Ophthalmology. 2014;121(1):202–208. DOI: 10.1016/j.ophtha.2013.08.012</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Choi K.E, Yun C., Cha J., Kim S.W. OCT angiography features associated with macular edema recurrence after intravitreal bevacizumab treatment in branch retinal vein occlusion. Sci Rep. 2019;9(1):14153. DOI: 10.1038/s41598-019-50637-8</mixed-citation><mixed-citation xml:lang="en">Choi K.E, Yun C., Cha J., Kim S.W. OCT angiography features associated with macular edema recurrence after intravitreal bevacizumab treatment in branch retinal vein occlusion. Sci Rep. 2019;9(1):14153. DOI: 10.1038/s41598-019-50637-8</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Jang J.H, Kim Y.C, Shin J.P. Correlation between macular edema recurrence and macular capillary network destruction in branch retinal vein occlusion. BMC Ophthalmol. 2020;20(1):341. DOI: 10.1186/s12886-020-01611-w</mixed-citation><mixed-citation xml:lang="en">Jang J.H, Kim Y.C, Shin J.P. Correlation between macular edema recurrence and macular capillary network destruction in branch retinal vein occlusion. BMC Ophthalmol. 2020;20(1):341. DOI: 10.1186/s12886-020-01611-w</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Aghdam A.K., Reznicek L, Sanjari S.M., Klingenstein A., Kernt M., Seidensticker F. Anti-VEGF treatment and peripheral retinal nonperfusion in patients with central retinal vein occlusion. Clin Ophthalmol. 2017;11:331–336. DOI: 10.2147/OPTH.</mixed-citation><mixed-citation xml:lang="en">Aghdam A.K., Reznicek L, Sanjari S.M., Klingenstein A., Kernt M., Seidensticker F. Anti-VEGF treatment and peripheral retinal nonperfusion in patients with central retinal vein occlusion. Clin Ophthalmol. 2017;11:331–336. DOI: 10.2147/OPTH.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Forooghian F., Kertes P.J, Eng K.T, Albiani D.A, Kirker A.W, Merkur A.B, Fallah N., Cao S., Cui J., Or C., Matsubara J.A. Alterations in intraocular cytokine levels following intravitreal ranibizumab. Can J Ophthalmol. 2016;51(2):87–90. DOI: 10.1016/j.jcjo.2015.11.001</mixed-citation><mixed-citation xml:lang="en">Forooghian F., Kertes P.J, Eng K.T, Albiani D.A, Kirker A.W, Merkur A.B, Fallah N., Cao S., Cui J., Or C., Matsubara J.A. Alterations in intraocular cytokine levels following intravitreal ranibizumab. Can J Ophthalmol. 2016;51(2):87–90. DOI: 10.1016/j.jcjo.2015.11.001</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Noma H., Yasuda K., Shimura M. Change of cytokines after intravitreal ranibizumab in patients with recurrent branch retinal vein occlusion and macular edema. Eur J Ophthalmol. 2021 Jan;31(1):204–210. DOI: 10.1177/1120672119885054</mixed-citation><mixed-citation xml:lang="en">Noma H., Yasuda K., Shimura M. Change of cytokines after intravitreal ranibizumab in patients with recurrent branch retinal vein occlusion and macular edema. Eur J Ophthalmol. 2021 Jan;31(1):204–210. DOI: 10.1177/1120672119885054</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Fujihara-Mino A., Mitamura Y., Inomoto N., Sano H., Akaiwa K., Semba K. Optical coherence tomography parameters predictive of visual outcome after anti-VEGF therapy for retinal vein occlusion. Clin Ophthalmol. 2016;10:1305–1313. DOI: 10.2147/</mixed-citation><mixed-citation xml:lang="en">Fujihara-Mino A., Mitamura Y., Inomoto N., Sano H., Akaiwa K., Semba K. Optical coherence tomography parameters predictive of visual outcome after anti-VEGF therapy for retinal vein occlusion. Clin Ophthalmol. 2016;10:1305–1313. DOI: 10.2147/</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Groneberg T., Trattnig J.S., Feucht N., Lohmann C.P., Maier M. Morphologic patterns on spectral-domain optical coherence tomography (SD-OCT) as a prognostic indicator in treatment of macular edema due to retinal vein occlusion. Klin Monbl Augenheilkd. 2016;233(9):1056–1062. DOI: 10.1055/s-0041-108680</mixed-citation><mixed-citation xml:lang="en">Groneberg T., Trattnig J.S., Feucht N., Lohmann C.P., Maier M. Morphologic patterns on spectral-domain optical coherence tomography (SD-OCT) as a prognostic indicator in treatment of macular edema due to retinal vein occlusion. Klin Monbl Augenheilkd. 2016;233(9):1056–1062. DOI: 10.1055/s-0041-108680</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Mimouni M., Segev О., Dori D. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with macular edema secondary to vein occlusion. Am. J. Ophthalmol. 2017;182:160–167.</mixed-citation><mixed-citation xml:lang="en">Mimouni M., Segev О., Dori D. Disorganization of the retinal inner layers as a predictor of visual acuity in eyes with macular edema secondary to vein occlusion. Am. J. Ophthalmol. 2017;182:160–167.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Шпак А.А. Новая номенклатура оптической когерентной томографии. Офтальмохирургия. 2015;3:80–82.</mixed-citation><mixed-citation xml:lang="en">Shpak A.A. New nomenclature of optical coherence tomography. Fyodorov Journal of Ophthalmic Surgery = Oftal’mokhirurgiya. 2015;3:80–82 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Будзинская М.В., Мазурина Н.К., Егоров А.Е., Куроедов А.В., Лоскутов И.А., Плюхова А.А., Разик С., Рябцева А.А., Симонова С.В. Алгоритм ведения пациентов с ретинальными венозными окклюзиями. Сообщение 2. Макулярный отек. Вестник офтальмологии. 2015;131(6):57–66. DOI: 10.17116/oftalma2015131657-66</mixed-citation><mixed-citation xml:lang="en">Budzinskaya M.V., Mazurina N.K., Egorov A.E., Kuroedov A.V., Loskutov I.A., Plyuhova A.A., Razik S., Ryabceva A.A., Simonova S.V. Algorithm for the management of patients with retinal venous occlusions. Message 2. Macular edema. Annals of Ophthalmology  = Vestnik oftal’mologii. 2015;131(6):57–66 (In Russ.). DOI: 10.17116/oftalma2015131657-66</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Еричев В.П., Козлова И.В., Косова Д.В., Аветисов К.С., Мазурова Ю.В. Динамика морфометрических параметров макулярной зоны у пациентов с глаукомой после факоэмульсификации. Вестник офтальмологии. 2019;135(52):129–134. DOI: 10.17116/oftalma2019135052129</mixed-citation><mixed-citation xml:lang="en">Erichev V.P., Kozlova I.V., Kosova D.V., Avetisov K.S., Mazurova Yu.V. Dynamics of the macular zone morphometric parameters in patients with glaucoma after phacoemulsification. Annals of Ophthalmology = Vestnik oftal’mologii. 2019;135(5-2):129–134 (In Russ.). DOI: 10.17116/oftalma2019135052129</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Будзинская М.В., Фурсова А.Ж., Педанова Е.К. Специфические биомаркеры ответа на антиангиогенную терапию. Вестник офтальмологии. 2020.;136(2):117–124. DOI: 10.17116/oftalma2020136021117</mixed-citation><mixed-citation xml:lang="en">Budzinskaya M.V., Fursova A.Zh., Pedanova E.K. Specific biomarkers of response to antiangiogenic therapy. Annals of Ophthalmology = Vestnik oftal’mologii. 2020;136(2):117–124 (In Russ.). DOI: 10.17116/oftalma2020136021117</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Jung S.H., Kim K.A., Sohn S.W., Yang S.J. Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion. Invest Ophthalmol Vis Sci. 2014 Apr 9;55(4):2290–2296. DOI: 10.1167/iovs.13-13587</mixed-citation><mixed-citation xml:lang="en">Jung S.H., Kim K.A., Sohn S.W., Yang S.J. Association of aqueous humor cytokines with the development of retinal ischemia and recurrent macular edema in retinal vein occlusion. Invest Ophthalmol Vis Sci. 2014 Apr 9;55(4):2290–2296. DOI: 10.1167/iovs.13-13587</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Дроздова Е.А., Хохлова Д.Ю. Динамическая оценка морфологических и иммунологических параметров при макулярном отеке на фоне окклюзии вен сетчатки. Практическая медицина. 2017;3(104):25–29.</mixed-citation><mixed-citation xml:lang="en">Drozdova E.A., Hohlova D.Yu. Dynamic assessment of morphological and immunological parameters in macular edema against the background of retinal vein occlusion. Practical medicine = Prakticheskaya meditsina. 2017;3(104):25–29 (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Ogino K., Murakami T., Tsujikawa A., Miyamoto K., Sakamoto A., Ota M., Yoshimura N. Characteristics of optical coherence tomographic hyperreflective foci in retinal vein occlusion. Retina. 2012 Jan;32(1):77–85. DOI: 10.1097/IAE.0b013e318217ffc7</mixed-citation><mixed-citation xml:lang="en">Ogino K., Murakami T., Tsujikawa A., Miyamoto K., Sakamoto A., Ota M., Yoshimura N. Characteristics of optical coherence tomographic hyperreflective foci in retinal vein occlusion. Retina. 2012 Jan;32(1):77–85. DOI: 10.1097/IAE.0b013e318217ffc7</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Do J.R., Park S.J., Shin J.P., Park D.H. Assessment of hyperreflective foci after bevacizumab or dexamethasone treatment according to duration of macular edema in patients with branch retinal vein occlusion. Retina. 2021 Feb 1;41(2):355–365. DOI: 10.1097/IAE.0000000000002826. PMID: 32349101</mixed-citation><mixed-citation xml:lang="en">Do J.R., Park S.J., Shin J.P., Park D.H. Assessment of hyperreflective foci after bevacizumab or dexamethasone treatment according to duration of macular edema in patients with branch retinal vein occlusion. Retina. 2021 Feb 1;41(2):355–365. DOI: 10.1097/IAE.0000000000002826. PMID: 32349101</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Dogan E., Sever O., Köklü Çakır B., Celik E. Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion. Clin Ophthalmol. 2018;17(12):1465–1470. DOI: 10.2147/OPTH.S162019</mixed-citation><mixed-citation xml:lang="en">Dogan E., Sever O., Köklü Çakır B., Celik E. Effect of intravitreal ranibizumab on serous retinal detachment in branch retinal vein occlusion. Clin Ophthalmol. 2018;17(12):1465–1470. DOI: 10.2147/OPTH.S162019</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Celık E., Doğan E., Turkoglu E.B., Çakır B., Alagoz G. Serous retinal detachment in patients with macular edema secondary to branch retinal vein occlusion. Arq Bras Oftalmol. 2016;79(1):9–11. DOI: 10.5935/0004-2749.20160004</mixed-citation><mixed-citation xml:lang="en">Celık E., Doğan E., Turkoglu E.B., Çakır B., Alagoz G. Serous retinal detachment in patients with macular edema secondary to branch retinal vein occlusion. Arq Bras Oftalmol. 2016;79(1):9–11. DOI: 10.5935/0004-2749.20160004</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Khokhlova D.Yu., Drozdova E.A.. Kurysheva N.I., Loskutov I.A. Optical coherence tomographic patterns in patients with retinal vein occlusion and macular edema treated by ranibizumab: a predictive and personalized approach. EPMA J. 2021 Mar 3;12(1):57–66. DOI: 10.1007/s13167-021-00233-6</mixed-citation><mixed-citation xml:lang="en">Khokhlova D.Yu., Drozdova E.A.. Kurysheva N.I., Loskutov I.A. Optical coherence tomographic patterns in patients with retinal vein occlusion and macular edema treated by ranibizumab: a predictive and personalized approach. EPMA J. 2021 Mar 3;12(1):57–66. DOI: 10.1007/s13167-021-00233-6</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Дроздова Е.А., Хохлова Д.Ю., Мезенцева Е.А., Никушкина К.В. Исследование системного и локального уровня цитокинов при окклюзии вен сетчатки на фоне антиангиогенной терапии. Медицинская иммунология. 2018;20(3):365–372. DOI: 10.15789/1563-06252018-3-365-372</mixed-citation><mixed-citation xml:lang="en">Drozdova E.A., Hohlova D.Yu., Mezenceva E.A., Nikushkina K.V. Investigation of the systemic and local cytokines level in retinal vein occlusion against the background of antiangiogenic therapy. Medical immunology (Russia) = Medicinskaya immunologiya. 2018;20(3):365–372 (In Russ.). DOI: 10.15789/1563-06252018-3-365-372</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
